Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Temozolomide in High-grade Gliomas
NCT04253873Phase 2Unknown
- Sponsor
- Huahui Health
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in glioma, sponsored by Huahui Health. Primary endpoint: 6-month Progression-Free Survival Rate. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04253873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253873.